Acquired resistance to immunotherapy and future challenges (original) (raw)

• Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269–281 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Khong, H. T. & Restifo, N. P. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat. Immunol. 3, 999–1005 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Restifo, N. P. et al. Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl Cancer Inst. 88, 100–108 (1996).
  Article CAS PubMed Google Scholar
• Pardoll, D. Cancer and the immune system: basic concepts and targets for intervention. Semin. Oncol. 42, 523–538 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Palmer, D. C. et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc. Natl Acad. Sci. USA 105, 8061–8066 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Prieto, P. A. et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin. Cancer Res. 18, 2039–2047 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ribas, A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 5, 915–919 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, B. J. et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res. 19, 3462–3473 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Spranger, S. et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci. Transl Med. 5, 200ra116 (2013).
  Article PubMed PubMed Central Google Scholar
• Markel, G. et al. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology 126, 186–200 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Landsberg, J. et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 490, 412–416 (2012).
  Article CAS PubMed Google Scholar
• Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412–7420 (2009).
  Article CAS PubMed Google Scholar
• Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
  Article PubMed PubMed Central Google Scholar
• Eggermont, A. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16, 522–530 (2015).
  Article CAS PubMed Google Scholar
• Thomas, L. On immunosurveillance in human cancer. Yale J. Biol. Med. 55, 329–333 (1982).
  CAS PubMed PubMed Central Google Scholar
• Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
  Article CAS PubMed Google Scholar
• Rammensee, H. G., Friede, T. & Stevanoviic, S. MHC ligands and peptide motifs: first listing. Immunogenetics 41, 178–228 (1995).
  Article CAS PubMed Google Scholar
• Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001).
  Article CAS PubMed Google Scholar
• O'Sullivan, T. et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J. Exp. Med. 209, 1869–1882 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Smyth, M. J. et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J. Exp. Med. 192, 755–760 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161–169 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903–907 (2007).
  Article CAS PubMed Google Scholar
• Matsushita, H. et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482, 400–404 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• DuPage, M., Mazumdar, C., Schmidt, L. M., Cheung, A. F. & Jacks, T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482, 405–409 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
  Article CAS PubMed Google Scholar
• Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).
  Article CAS PubMed Google Scholar
• Joyce, J. A. & Fearon, D. T. T cell exclusion, immune privilege, and the tumor microenvironment. Science 348, 74–80 (2015).
  Article CAS PubMed Google Scholar
• Rajasagi, M. et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 124, 453–462 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Gattinoni, L., Klebanoff, C. A. & Restifo, N. P. Paths to stemness: building the ultimate antitumour T cell. Nat. Rev. Cancer 12, 671–684 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Klebanoff, C.A., Rosenberg, S.A. & Restifo, N.P. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat. Med. 22, 26–36 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Snyder, A. et al. Genetics and immunology: reinvigorated. Oncoimmunology 4, e1029705 (2015).
  Article PubMed PubMed Central Google Scholar
• Snyder, A., Wolchok, J. D. & Chan, T. A. Genetic basis for clinical response to CTLA-4 blockade. N. Engl. J. Med. 372, 783 (2015).
  Article CAS PubMed Google Scholar
• Gubin, M. M. & Schreiber, R. D. The odds of immunotherapy success. Science 350, 158–159 (2015).
  Article CAS PubMed Google Scholar
• Teng, M. W., Ngiow, S. F., Ribas, A. & Smyth, M. J. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 75, 2139–2145 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Taube, J. M. et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20, 5064–5074 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Postow, M. A. et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006–2017 (2015).
  Article PubMed PubMed Central Google Scholar
• Victor, C. T. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015).
  Article PubMed Central Google Scholar
• Liu, S. V. P. J. et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 33 (15 Suppl.), 8030 (2015).
  Article Google Scholar
• John, L. B. et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin. Cancer Res. 19, 5636–5646 (2013).
  Article CAS PubMed Google Scholar
• Saltz, L. B. Can money really be no object when cancer care is the subject? J. Clin. Oncol. 33, 1093–1094 (2015).
  Article PubMed Google Scholar